APAC Acute LymphocyticLymphoblastic Leukemia (ALL) Diagnostics Market

Description

List of Tables

The Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market is projected to register a substantial CAGR of 8.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030

Market Segmentation:

Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

Rise in preference for preventive health check-ups

Increase in awareness about the leukemia cancer diagnostics

Market Players:

Some of the major players operating in the Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Merck KGaA

Siemens Medical Solutions USA, Inc.

Hologic, Inc.

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

Myriad Genetics, Inc.

bioMerieux SA

Quest Diagnostics Incorporated

Bio-Rad Laboratories, Inc.

Koninklijke Philips N.V.

Exact Sciences Corporation

Time Medical Holding

PlexBio

MinFound Medical Systems Co., Ltd

Medonica Co. LTD

1 INTRODUCTION 54

1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 57

2 MARKET SEGMENTATION 60

2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 PRODUCT TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET TESTING TYPE COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72

3 EXECUTIVE SUMMARY 73

4 PREMIUM INSIGHTS 76

4.1 PESTEL ANALYSIS 77
4.2 PORTER'S FIVE FORCES 78
4.3 INDUSTRY INSIGHTS 79

5 EPIDEMIOLOGY 81

6 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 82

7 MARKET OVERVIEW 85

7.1 DRIVERS 87
- 7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
- 7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
- 7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
- 7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 88
7.2 RESTRAINTS 90
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 90
- 7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 91
7.3 OPPORTUNITIES 91
- 7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 91
- 7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 92
- 7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 92
7.4 CHALLENGES 93
- 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
- 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94

8 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 95

8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
- 8.2.1 BIOPSY INSTRUMENTS 100
  - 8.2.1.1 BONE MARROW BIOPSY 100
  - 8.2.1.2 NEEDLE BIOPSY 100
  - 8.2.1.3 SURGEON BIOPSY 101
  - 8.2.1.4 OTHERS 101
- 8.2.2 PATHOLOGY-BASED INSTRUMENTS 101
  - 8.2.2.1 PCR INSTRUMENTS 101
  - 8.2.2.2 SLIDE STAINING SYSTEMS 101
  - 8.2.2.3 TISSUE PROCESSING SYSTEMS 101
  - 8.2.2.4 CELL PROCESSORS 102
  - 8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 102
- 8.2.3 IMAGING INSTRUMENTS 102
  - 8.2.3.1 ULTRASOUND SYSTEMS 102
  - 8.2.3.2 CT SYSTEMS 102
  - 8.2.3.3 MRI SYSTEMS 102
  - 8.2.3.4 OTHERS 103
- 8.2.4 OTHERS 103
8.3 CONSUMABLES & ACCESSORIES 103
- 8.3.1 KITS 104
  - 8.3.1.1 PCR KITS 104
  - 8.3.1.2 DNA POLYMERASE KITS 104
  - 8.3.1.3 NUCLEIC ACID ISOLATION KITS 104
  - 8.3.1.4 OTHERS 105
- 8.3.2 REAGENTS 105
  - 8.3.2.1 ASSAYS 105
  - 8.3.2.2 BUFFERS 105
  - 8.3.2.3 PRIMERS 105
  - 8.3.2.4 OTHERS 105
- 8.3.3 PROBES 106
- 8.3.4 OTHER CONSUMABLES 106

9 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 107

9.1 OVERVIEW 108
9.2 BIOPSY 111
- 9.2.1 BONE MARROW BIOPSY 112
- 9.2.2 NEEDLE BIOPSY 112
- 9.2.3 SURGEON BIOPSY 112
- 9.2.4 OTHERS 112
9.3 BLOOD TEST 113
- 9.3.1 BLOOD CHEMISTRY TESTS 114
- 9.3.2 COMPLETE BLOOD COUNT (CBC) 114
- 9.3.3 OTHERS 114
9.4 IMAGING TEST 114
- 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
- 9.4.2 MRI 115
- 9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 116
- 9.4.4 OTHERS 116
9.5 OTHERS 116

10 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 117

10.1 OVERVIEW 118
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 121
- 10.2.1 EARLY PRE-B ALL 122
- 10.2.2 COMMON ALL 122
- 10.2.3 PRE-B ALL 122
- 10.2.4 MATURE B-CELL ALL 122
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 122
- 10.3.1 PRE-T ALL 123
- 10.3.2 MATURE T-CELL ALL 123

11 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 124

11.1 OVERVIEW 125
11.2 BELOW 21 128
11.3 21-29 129
11.4 30-65 130
11.5 65 AND ABOVE 131

12 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 132

12.1 OVERVIEW 133
12.2 MALE 136
12.3 FEMALE 137

13 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 138

13.1 OVERVIEW 139
13.2 HOSPITALS 142
13.3 ASSOCIATED LABS 142
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 143
13.5 DIAGNOSTIC IMAGING CENTERS 144
13.6 CANCER RESEARCH INSTITUTES 144
13.7 OTHERS 145

14 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 146

14.1 OVERVIEW 147
14.2 DIRECT TENDER 150
14.3 RETAIL SALES 151

15 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 152

15.1 ASIA-PACIFIC 153
- 15.1.1 CHINA 164
- 15.1.2 JAPAN 169
- 15.1.3 INDIA 174
- 15.1.4 AUSTRALIA 179
- 15.1.5 INDONESIA 184
- 15.1.6 SOUTH KOREA 189
- 15.1.7 VIETNAM 195
- 15.1.8 THAILAND 200
- 15.1.9 PHILIPPINES 205
- 15.1.10 MALAYSIA 210
- 15.1.11 SINGAPORE 215
- 15.1.12 REST OF ASIA PACIFIC 220

16 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 221

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 221

17 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 222

17.1 F. HOFFMANN-LA ROCHE LTD. 222
- 17.1.1 COMPANY SNAPSHOT 222
- 17.1.2 REVENUE ANALYSIS 222
- 17.1.3 COMPANY SHARE ANALYSIS 223
- 17.1.4 PRODUCT PORTFOLIO 223
- 17.1.5 RECENT DEVELOPMENT 223
17.2 THERMO FISHER SCIENTIFIC INC. 224
- 17.2.1 COMPANY SNAPSHOT 224
- 17.2.2 REVENUE ANALYSIS 224
- 17.2.3 COMPANY SHARE ANALYSIS 225
- 17.2.4 PRODUCT PORTFOLIO 225
- 17.2.5 RECENT DEVELOPMENT 225
17.3 QIAGEN 226
- 17.3.1 COMPANY SNAPSHOT 226
- 17.3.2 REVENUE ANALYSIS 226
- 17.3.3 COMPANY SHARE ANALYSIS 227
- 17.3.4 PRODUCT PORTFOLIO 227
- 17.3.5 RECENT DEVELOPMENT 227
17.4 ABBOTT 228
- 17.4.1 COMPANY SNAPSHOT 228
- 17.4.2 REVENUE ANALYSIS 228
- 17.4.3 COMPANY SHARE ANALYSIS 229
- 17.4.4 PRODUCT PORTFOLIO 229
- 17.4.5 RECENT DEVELOPMENT 229
17.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 230
- 17.5.1 COMPANY SNAPSHOT 230
- 17.5.2 REVENUE ANALYSIS 230
- 17.5.3 COMPANY SHARE ANALYSIS 231
- 17.5.4 PRODUCT PORTFOLIO 231
- 17.5.5 RECENT DEVELOPMENT 231
17.6 MERCK KGAA 232
- 17.6.1 COMPANY SNAPSHOT 232
- 17.6.2 REVENUE ANALYSIS 232
- 17.6.3 PRODUCT PORTFOLIO 233
- 17.6.4 RECENT DEVELOPMENT 233
17.7 HOLOGIC INC. 234
- 17.7.1 COMPANY SNAPSHOT 234
- 17.7.2 REVENUE ANALYSIS 234
- 17.7.3 PRODUCT PORTFOLIO 235
- 17.7.4 RECENT DEVELOPMENT 235
17.8 AGILENT TECHNOLOGIES, INC. 236
- 17.8.1 COMPANY SNAPSHOT 236
- 17.8.2 REVENUE ANALYSIS 236
- 17.8.3 PRODUCT PORTFOLIO 237
- 17.8.4 RECENT DEVELOPMENT 237
17.9 BD 238
- 17.9.1 COMPANY SNAPSHOT 238
- 17.9.2 REVENUE ANALYSIS 238
- 17.9.3 PRODUCT PORTFOLIO 239
- 17.9.4 RECENT DEVELOPMENT 239
17.10 BIOMERIEUX SA 240
- 17.10.1 COMPANY SNAPSHOT 240
- 17.10.2 REVENUE ANALYSIS 240
- 17.10.3 PRODUCT PORTFOLIO 241
- 17.10.4 RECENT DEVELOPMENTS 241
17.11 BIO-RAD LABORATORIES, INC. 242
- 17.11.1 COMPANY SNAPSHOT 242
- 17.11.2 REVENUE ANALYSIS 242
- 17.11.3 PRODUCT PORTFOLIO 243
- 17.11.4 RECENT DEVELOPMENT 243
17.12 DIASORIN S.P.A. 244
- 17.12.1 COMPANY SNAPSHOT 244
- 17.12.2 REVENUE ANALYSIS 244
- 17.12.3 PRODUCT PORTFOLIO 245
- 17.12.4 RECENT DEVELOPMENTS 245
17.13 EXACT SCIENCE CORPORATION 246
- 17.13.1 COMPANY SNAPSHOT 246
- 17.13.2 REVENUE ANALYSIS 246
- 17.13.3 PRODUCT PORTFOLIO 247
- 17.13.4 RECENT DEVELOPMENT 247
17.14 ILLUMINA, INC. 248
- 17.14.1 COMPANY SNAPSHOT 248
- 17.14.2 REVENUE ANALYSIS 248
- 17.14.3 PRODUCT PORTFOLIO 249
- 17.14.4 RECENT DEVELOPMENT 249
17.15 KONINKLIJKE PHILIPS N.V. 250
- 17.15.1 COMPANY SNAPSHOT 250
- 17.15.2 REVENUE ANALYSIS 250
- 17.15.3 PRODUCT PORTFOLIO 251
- 17.15.4 RECENT DEVELOPMENT 251
17.16 MEDONICA CO. LTD 252
- 17.16.1 COMPANY SNAPSHOT 252
- 17.16.2 PRODUCT PORTFOLIO 252
- 17.16.3 RECENT DEVELOPMENT 252
17.17 MICHAEL DIAGNOSTICS LTD 253
- 17.17.1 COMPANY SNAPSHOT 253
- 17.17.2 PRODUCT PORTFOLIO 253
- 17.17.3 RECENT DEVELOPMENT 253
17.18 MINFOUND MEDICAL SYSTEMS CO., LTD 254
- 17.18.1 COMPANY SNAPSHOT 254
- 17.18.2 PRODUCT PORTFOLIO 254
- 17.18.3 RECENT DEVELOPMENT 254
17.19 MYRIAD GENETICS, INC. 255
- 17.19.1 COMPANY SNAPSHOT 255
- 17.19.2 REVENUE ANALYSIS 255
- 17.19.3 PRODUCT PORTFOLIO 256
- 17.19.4 RECENT DEVELOPMENT 256

17.20 PLEXBIO 257
- 17.20.1 COMPANY SNAPSHOT 257
- 17.20.2 PRODUCT PORTFOLIO 257
- 17.20.3 RECENT DEVELOPMENTS 257
17.21 QUEST DIAGNOSTICS INCORPORATED 258
- 17.21.1 COMPANY SNAPSHOT 258
- 17.21.2 REVENUE ANALYSIS 258
- 17.21.3 PRODUCT PORTFOLIO 259
- 17.21.4 RECENT DEVELOPMENTS 259
17.22 STERNMED GMBH 260
- 17.22.1 COMPANY SNAPSHOT 260
- 17.22.2 PRODUCT PORTFOLIO 260
- 17.22.3 RECENT DEVELOPMENTS 260
17.23 TIME MEDICAL HOLDING 261
- 17.23.1 COMPANY SNAPSHOT 261
- 17.23.2 PRODUCT PORTFOLIO 261
- 17.23.3 RECENT DEVELOPMENT 261

18 QUESTIONNAIRE 262

19 RELATED REPORTS 266

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 67
TABLE 2 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 74
TABLE 3 ASIA PACIFIC INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 4 ASIA PACIFIC INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76
TABLE 5 ASIA PACIFIC BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76
TABLE 6 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77
TABLE 7 ASIA PACIFIC IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 78
TABLE 8 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 9 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 80
TABLE 10 ASIA PACIFIC KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 80
TABLE 11 ASIA PACIFIC REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 81
TABLE 12 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 86
TABLE 13 ASIA PACIFIC BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 14 ASIA PACIFIC BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 88
TABLE 15 ASIA PACIFIC BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 16 ASIA PACIFIC BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 90
TABLE 17 ASIA PACIFIC IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 18 ASIA PACIFIC IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 91
TABLE 19 ASIA PACIFIC OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 20 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 96
TABLE 21 ASIA PACIFIC B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 22 ASIA PACIFIC B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 98
TABLE 23 ASIA PACIFIC T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 24 ASIA PACIFIC T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 99
TABLE 25 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 103
TABLE 26 ASIA PACIFIC BELOW 21 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 27 ASIA PACIFIC 21-29 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 28 ASIA PACIFIC 30-65 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 29 ASIA PACIFIC 65 AND ABOVE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 30 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 111
TABLE 31 ASIA PACIFIC MALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 32 ASIA PACIFIC FEMALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 33 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 34 ASIA PACIFIC HOSPITALS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 35 ASIA PACIFIC ASSOCIATED LABS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 36 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 37 ASIA PACIFIC DIAGNOSTIC IMAGING CENTER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 38 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 39 ASIA PACIFIC OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 40 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 125
TABLE 41 ASIA PACIFIC DIRECT TENDER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
TABLE 42 ASIA PACIFIC RETAIL SALES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
TABLE 43 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 134
TABLE 44 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 45 ASIA-PACIFIC INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 46 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
TABLE 47 ASIA-PACIFIC IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
TABLE 48 ASIA-PACIFIC BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
TABLE 49 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 50 ASIA-PACIFIC KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 51 ASIA-PACIFIC REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 52 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
TABLE 53 ASIA-PACIFIC IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 54 ASIA-PACIFIC BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 55 ASIA-PACIFIC BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 56 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 137
TABLE 57 ASIA-PACIFIC B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 138
TABLE 58 ASIA-PACIFIC T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 138
TABLE 59 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 138
TABLE 60 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 138
TABLE 61 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
TABLE 62 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 139
TABLE 63 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 64 CHINA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 65 CHINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 66 CHINA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 67 CHINA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 68 CHINA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 69 CHINA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 70 CHINA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
TABLE 71 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 72 CHINA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 73 CHINA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 74 CHINA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 75 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 76 CHINA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 77 CHINA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 78 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 144
TABLE 79 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 144
TABLE 80 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
TABLE 81 CHINA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
TABLE 82 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 83 JAPAN INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 84 JAPAN PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 85 JAPAN IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 86 JAPAN BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 87 JAPAN CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 88 JAPAN KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 89 JAPAN REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 90 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 91 JAPAN IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 92 JAPAN BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 93 JAPAN BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 94 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 148
TABLE 95 JAPAN B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 148
TABLE 96 JAPAN T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 148
TABLE 97 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 149
TABLE 98 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 149
TABLE 99 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 149
TABLE 100 JAPAN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 149
TABLE 101 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
TABLE 102 INDIA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
TABLE 103 INDIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
TABLE 104 INDIA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 105 INDIA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 106 INDIA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 107 INDIA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 108 INDIA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 109 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 110 INDIA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 111 INDIA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 112 INDIA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
TABLE 113 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 153
TABLE 114 INDIA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 153
TABLE 115 INDIA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 153
TABLE 116 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 154
TABLE 117 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 154
TABLE 118 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 154
TABLE 119 INDIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 154
TABLE 120 AUSTRALIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 155
TABLE 121 AUSTRALIA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 155
TABLE 122 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 155
TABLE 123 AUSTRALIA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 156

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 35
FIGURE 2 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DATA TRIANGULATION 38
FIGURE 3 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DROC ANALYSIS 39
FIGURE 4 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 40
FIGURE 5 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 40
FIGURE 6 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 42
FIGURE 7 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 43
FIGURE 8 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID 45
FIGURE 9 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 46
FIGURE 10 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 50
FIGURE 11 INCREASE IN THE AWARENESS ABOUT LEUKEMIA IS EXPECTED TO DRIVE THE ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN THE FORECAST PERIOD 51
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN 2023 & 2030 51
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ACUTE LYMPHOCYTIC/ LYMPHOBLASTIC (ALL) LEUKEMIA DIAGNOSTICS MARKET 61
FIGURE 14 ASIA PACIFIC LEUKEMIA INCIDENCE (BOTH SEXES) 64
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE (BOTH SEXES) 65
FIGURE 16 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 71
FIGURE 17 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 72
FIGURE 18 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 72
FIGURE 19 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY PRODUCT TYPE, LIFELINE CURVE 73
FIGURE 20 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2022 83
FIGURE 21 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 84
FIGURE 22 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 84
FIGURE 23 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 85
FIGURE 24 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 93
FIGURE 25 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 94
FIGURE 26 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 94
FIGURE 27 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 95
FIGURE 28 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2022 100
FIGURE 29 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 101
FIGURE 30 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 101
FIGURE 31 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 102
FIGURE 32 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2022 108
FIGURE 33 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 109
FIGURE 34 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 109
FIGURE 35 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY GENDER, LIFELINE CURVE 110
FIGURE 36 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2022 114
FIGURE 37 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 115
FIGURE 38 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 115
FIGURE 39 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 116
FIGURE 40 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 122
FIGURE 41 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 123
FIGURE 42 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 123
FIGURE 43 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 124
FIGURE 44 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 129
FIGURE 45 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 131
FIGURE 46 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 131
FIGURE 47 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 132
FIGURE 48 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 132
FIGURE 49 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 196